NYSEAMERICAN:MTNB Matinas Biopharma Q3 2025 Earnings Report $0.16 0.00 (-1.60%) As of 09/18/2026 04:10 PM Eastern ProfileEarnings History Matinas Biopharma EPS ResultsActual EPS-$0.40Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMatinas Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMatinas Biopharma Announcement DetailsQuarterQ3 2025Date11/10/2025TimeBefore Market OpensConference Call DateMonday, November 10, 2025Conference Call Time4:00PM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly Report(10-Q) Matinas Biopharma Earnings HeadlinesMatinas Biopharma (NYSEAMERICAN:MTNB) Shares Set to Reverse Split on Monday, September 28thSeptember 20 at 1:20 AM | americanbankingnews.comGH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility OutputSeptember 14, 2026 | globenewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 20 at 1:00 AM | Stansberry Research (Ad)Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsSeptember 4, 2026 | globenewswire.comGH Power, Matinas BioPharma join forces to create NYSE-listed clean energy companyJuly 13, 2026 | msn.comMatinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement ...July 13, 2026 | markets.businessinsider.comSee More Matinas Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Matinas Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Matinas Biopharma and other key companies, straight to your email. Email Address About Matinas BiopharmaMatinas Biopharma (NYSEAMERICAN:MTNB) is a clinical-stage biopharmaceutical company focused on developing oral formulations of medicines that are traditionally administered by injection. The company’s technology platform, known as lipid nanocrystal (LNC) technology, is designed to encapsulate active pharmaceutical ingredients and support their delivery through the gastrointestinal tract. Matinas’ lead investigational product is MAT2203, an oral formulation of amphotericin B, an antifungal medicine used to treat serious fungal infections. The company has evaluated MAT2203 in clinical studies for conditions including cryptococcal meningitis and other invasive fungal infections. The product remains investigational and is not approved for commercial use. The company has also developed additional LNC-based programs, including MAT2501, an investigational oral formulation of amikacin intended for potential use in treating certain difficult-to-manage bacterial infections. Matinas BioPharma is headquartered in the United States and has focused its activities on research, clinical development and potential partnerships for its drug-delivery platform and product candidates.View Matinas Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
